85% of the way ?Readers of Kellums last paper on Bayesian analysis in the context of the phase 3 (Euphrates) and 3b Trial (Tigris) understand that the results are statistically analyzed together ( with slightly different weightings for each ) and why we are likely 85-90% of the way. And the burden of proof is getting lighter and lighter ( see revised 7% ARR needed, despite an at expectation of 10% or more. Now factor in a exceeding expectation for the Tigris Trial and its no wonder that The Paradigm analysts is calling the outcome an all but foregone conclusion. This of course begs the question as to whether or not the FDA will insist on an enrolment of the last 60 (or 50, or 40) when lives are at stake, with an open label trial where Dr.s are neither blind to the effects of PMX, nor to the impact of this novel and proven treatment on their patients lives. MM